Literature DB >> 27096595

Ibrutinib for Chronic Lymphocytic Leukemia.

Jeff P Sharman1, Anthony R Mato2, Michael J Keating3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27096595     DOI： 10.1056/NEJMc1600328

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

2.  Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.

Authors:  Talal Hilal; Mohamad Bassam Sonbol; Vinay Prasad
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

Review 3.  A Systematic Review to Assess the Relationship between Disseminated Cerebral Aspergillosis, Leukemias and Lymphomas, and Their Respective Therapeutics.

Authors:  Brianne N Sullivan; Mia A Baggett; Samantha S O'Connell; Keith M Pickett; Chad Steele
Journal:  J Fungi (Basel)       Date:  2022-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.